Back to Results
First PageMeta Content
Diabetes / Eli Lilly and Company / Hypoglycemia / Insulin / Diabetes mellitus / Glucokinase / Metformin / Insulin therapy / Diabetes management / Medicine / Endocrine system / Biology


Document Date: 2015-03-08 13:11:53

Open Document

File Size: 105,38 KB

Share Result on Facebook

City

Shanghai / San Francisco / /

Company

AEs / Fidelity Growth Partners Asia / Hua Medicine / /

Country

United States / China / /

Currency

USD / /

Event

FDA Phase / Funding / /

IndustryTerm

experienced / biotechnology / diabetes therapies / diabetes therapy / treatment of diabetes / apparent food effect / /

MedicalCondition

Depressive Disorder / heart disease / Diabetes / dyskinesia / CNS disorders / kidney failure / Parkinson’s Disease / hypoglycemia / very promising diabetes / oral diabetes / blindness / /

Organization

CFDA / Hua Medicine’s Portfolio Advisory Board / American Diabetes Association / /

Person

Li Chen / John Baldwin / Daniel Auerbach / Yi Zhang / /

Position

Managing Partner / CEO / Chair / Head / /

Product

China / US / Diabetes / 2Q2016 / /

Technology

Pharmacokinetics / drug discovery / biotechnology / Pharmacodynamics / drug development / /

SocialTag